Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor Obtains Milestone Payment From Pfizer
Xencor has obtained a milestone payment from Pfizer. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of
Xencor has obtained a milestone payment from Pfizer. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of
ChemoCentryx has initiated patient enrollment in a Phase 2 clinical trial of CCX354, an orally-bioavailable, small molecule drug, designed to specifically target the CCR1 chemokine receptor for the
Roche has licensed its P2X31 receptor program aimed at developing treatments for chronic pain to Afferent Pharmaceuticals (Afferent). In conjunction with the announcement, Afferent has successfully closed a
ThromboGenics has completed the enrollment of the second Phase III trial evaluating Microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both in
Diagnostic Nano Technology (DNA), a subsidiary of Avisio, has reported that with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that
Keryx Biopharmaceuticals, (Keryx) has initiated Phase 3 registration clinical trial for KRX-0401 (perifosine), a PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial, entitled, ‘A
The Medicines has reported that it is voluntarily recalling eleven lots of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has
Advanced Life Sciences has reported positive top-line results from a pivotal, non-human primate study of its once-a-day, oral antibiotic Restanza (cethromycin) against an inhaled lethal dose of Tularemia.
Onset Therapeutics (Onset) has reported positive results from a skin moisturisation study that compared the company’s recently launched BenzEFoam (benzoyl peroxide 5.3%) emollient foam to combination gel containing
OSI Pharmaceuticals and Genentech, a wholly owned member of the Roche Group have reported that the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against